Is the Medicare GLP-1 Bridge available in 2026?

Yes, and it carries a published end date of 2027-12-31, 447 days from the last time this page rebuilt. The terms above were read on 2026-09-05.

When does the Medicare GLP-1 Bridge end?

Centers for Medicare & Medicaid Services publishes an end date of 2027-12-31, which is 447 days from the last time this page rebuilt. Any site still quoting the price after that date is quoting an offer that no longer exists.

← Every GLP-1 savings program

Medicare GLP-1 Bridge

Centers for Medicare & Medicaid Services publishes this at $50 a month. Medicare route — not a manufacturer card, and separate from those cards, which exclude Medicare.

Last updated 2026-09-05 — the last time this offer was read from Centers for Medicare & Medicaid Services' own page. Read and dated by Alex Seot.

What does the Medicare GLP-1 Bridge actually get you?

Centers for Medicare & Medicaid Services publishes the Medicare GLP-1 Bridge at $50 a month. It is a Medicare route, run by Centers for Medicare & Medicaid Services rather than by a manufacturer, and it needs the prescriber's prior authorization. The manufacturer savings cards stay closed to anyone on Medicare, so the two never stack. The condition attached: The $50 does not count toward your Part D deductible or the out-of-pocket maximum, because the demonstration sits outside Part D coverage rather than inside it. It carries a published end date of 2027-12-31, after which any site still quoting it is quoting a price that no longer exists. 2 other programs run for Zepbound, and they answer different situations rather than competing on price. A price checked more than 45 days ago is marked stale on this site rather than quietly aging. Every figure here is read from the sponsor's own published page on the date shown.

Dated offer. Centers for Medicare & Medicaid Services publishes an end date of 2027-12-31 — 447 days out.

The terms, as published

Price: $50 a month
Who for: Part D beneficiaries 18 or older whose prescriber submits a prior authorization attesting the drug treats obesity, and who have a BMI of 35 or higher, a BMI of 30 or higher with diastolic heart failure, uncontrolled hypertension or stage 3a chronic kidney disease, or a BMI of 27 or higher with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease. Not for anyone with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease, or whose Part D plan already covers a GLP-1. Covers all formulations of Foundayo and Wegovy, and the KwikPen formulation of Zepbound only — not the single-dose Zepbound vials or pens.
The catch: The $50 does not count toward your Part D deductible or the out-of-pocket maximum, because the demonstration sits outside Part D coverage rather than inside it. It is also time-limited: a demonstration under Section 402 authority, not a benefit.
Ends: 2027-12-31
Source: www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providersread 2026-09-05

If you are on Medicare

This is the case the Medicare GLP-1 Bridge is for, once the conditions in its eligibility line above are met. The manufacturer savings cards stay closed to you whatever your plan: federal anti-kickback rules bar them from anyone on a federal program.

If you are not on Medicare

The Medicare GLP-1 Bridge does not apply. The cash route for Zepbound is Zepbound Journey Program. With a commercial plan that covers Zepbound, Zepbound savings card is the copay card. Getting the plan to cover it is the other route, and it is worth trying before settling for a cash price.

Which drugs it covers

Medicare GLP-1 Bridge is not one drug's program, which is why the price it has to beat is not one figure. Part D beneficiaries 18 or older whose prescriber submits a prior authorization attesting the drug treats obesity, and who have a BMI of 35 or higher, a BMI of 30 or higher with diastolic heart failure, uncontrolled hypertension or stage 3a chronic kidney disease, or a BMI of 27 or higher with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease. Not for anyone with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease, or whose Part D plan already covers a GLP-1. Covers all formulations of Foundayo and Wegovy, and the KwikPen formulation of Zepbound only — not the single-dose Zepbound vials or pens.

Foundayo programs and prices — $299 a month with no program, read from its own published page on 2026-09-12.
Wegovy pill programs and prices — $299 a month with no program, read from its own published page on 2026-09-10.
Wegovy programs and prices — $349 a month with no program, read from its own published page on 2026-09-22.
Zepbound programs and prices — $449 a month with no program, read from its own published page on 2026-08-19, 51 days ago and past the 45-day window.

Each of those pages lists this program beside the manufacturer's own, with the figure that drug costs when nothing applies.

The other 2 programs for Zepbound

Zepbound Journey Program
$449 a month at 7.5 mg and above. Self-pay price — the figure with insurance out of the picture.
Zepbound savings card
As little as $25 for up to a 3-month prescription. Copay card — needs insurance that already covers the drug.

Zepbound price and terms →All Zepbound programs →Zepbound side effects →Does insurance cover it →Appeal a denial →

Questions about the Medicare GLP-1 Bridge

How can I get a GLP-1 for $50 a month on Medicare?: $50 is what the Medicare GLP-1 Bridge costs you once you qualify for it — not a price anyone can buy at. Part D beneficiaries 18 or older whose prescriber submits a prior authorization attesting the drug treats obesity, and who have a BMI of 35 or higher, a BMI of 30 or higher with diastolic heart failure, uncontrolled hypertension or stage 3a chronic kidney disease, or a BMI of 27 or higher with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease. Not for anyone with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease, or whose Part D plan already covers a GLP-1. Covers all formulations of Foundayo and Wegovy, and the KwikPen formulation of Zepbound only — not the single-dose Zepbound vials or pens. The $50 does not count toward your Part D deductible or the out-of-pocket maximum, because the demonstration sits outside Part D coverage rather than inside it. It is also time-limited: a demonstration under Section 402 authority, not a benefit.
Who qualifies for the Medicare GLP-1 Bridge?: Part D beneficiaries 18 or older whose prescriber submits a prior authorization attesting the drug treats obesity, and who have a BMI of 35 or higher, a BMI of 30 or higher with diastolic heart failure, uncontrolled hypertension or stage 3a chronic kidney disease, or a BMI of 27 or higher with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease. Not for anyone with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease, or whose Part D plan already covers a GLP-1. Covers all formulations of Foundayo and Wegovy, and the KwikPen formulation of Zepbound only — not the single-dose Zepbound vials or pens. Read from Centers for Medicare & Medicaid Services' own page on 2026-09-05.
Is the Medicare GLP-1 Bridge available in 2026?: Yes, and it carries a published end date of 2027-12-31, 447 days from the last time this page rebuilt. The terms above were read on 2026-09-05.
Do I need insurance to use the Medicare GLP-1 Bridge?: Yes: Medicare drug coverage. Part D beneficiaries 18 or older whose prescriber submits a prior authorization attesting the drug treats obesity, and who have a BMI of 35 or higher, a BMI of 30 or higher with diastolic heart failure, uncontrolled hypertension or stage 3a chronic kidney disease, or a BMI of 27 or higher with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease. Not for anyone with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease, or whose Part D plan already covers a GLP-1. Covers all formulations of Foundayo and Wegovy, and the KwikPen formulation of Zepbound only — not the single-dose Zepbound vials or pens. It is a Medicare route rather than a commercial one, and the manufacturer savings cards, which exclude anyone on Medicare, never stack with it.
What is the catch on the Medicare GLP-1 Bridge?: The $50 does not count toward your Part D deductible or the out-of-pocket maximum, because the demonstration sits outside Part D coverage rather than inside it. It is also time-limited: a demonstration under Section 402 authority, not a benefit.
When does the Medicare GLP-1 Bridge end?: Centers for Medicare & Medicaid Services publishes an end date of 2027-12-31, which is 447 days from the last time this page rebuilt. Any site still quoting the price after that date is quoting an offer that no longer exists.

halfrx is not affiliated with Centers for Medicare & Medicaid Services and is paid nothing for listing this. Every figure is read from Centers for Medicare & Medicaid Services' own page on the date shown. Information only, not medical advice.

Medicare's own documents

What Medicare publishes on weight-loss drugs, the statute listing drugs a program may exclude, and why the manufacturer cards stay closed to Medicare.

Social Security Act §1927(d)(2), Office of the Law Revision Counsel — The statute itself, listing “agents when used for anorexia, weight loss, or weight gain” among the drugs a program may exclude.
Manufacturer safeguards may not prevent copayment coupon use for Part D drugs, HHS Office of Inspector General — Why a manufacturer copay card cannot be used with a federal program, from the office that enforces it.
Weight-loss drugs, Medicare.gov — Medicare's own page on what it does and does not cover for weight loss.